
All Provinces and Territories Sign Rare Disease Drug Agreements
Ottawa, April 1, 2025 – Quebec signed a bilateral agreement under the federal government’s National Strategy for Drugs for Rare […]
Put your finger on the pulse of the healthcare industry.
For media inquiries, please contact us at media@imc-mnc.ca or 613-462-5367.
Ottawa, April 1, 2025 – Quebec signed a bilateral agreement under the federal government’s National Strategy for Drugs for Rare […]
Ottawa, March 21, 2025 – With the imminent announcement of a federal election, Canadians have an opportunity to reflect on the […]
Toronto, December 16, 2024 – Innovative Medicines Canada (IMC) welcomes the collective agreement amongst Canada’s Premiers to take meaningful action […]
This article originally appeared in Saltwire newspapers across Atlantic Canada on July 11, 2024. Dr. P.J. Devereaux, co-chair of Accelerating Clinical Trials […]
This article originally appeared in the The Globe and Mail on March 4, 2024. Strong gender representation in workplace leadership helps businesses […]
Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.
Industry Association Applauds Commitment to the Stratégie Québécoise des sciences de la vie (2025-2028) and to Pharmaceuticals in Hospital Settings […]
Ottawa, February 3, 2025 – Innovative Medicines Canada (IMC) is pleased to welcome Patrick Hupé, M.Sc., MBA, as Vice President […]
Ottawa, December 16, 2024 – Following the release of the Fall Economic Statement, Innovative Medicines Canada (IMC) is calling on […]
Get in touch Please complete the form below, and a representative will be in touch as soon as possible. Departments […]
At Innovative Medicines Canada, we offer sponsorship opportunities to facilitate research, generate awareness, create educational programs, and improve access to innovative medicines.
Sign up to our newsletter to get our latest news and updates.
Browse by topic
Informative content to keep you up to date on the most pressing issues facing our industry.